Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Cordiali Fei, Paola ^a   Mussi, Anna ^a   D'Agosto, Giovanna ^a   Trento, Elisabetta ^a   Bordignon, Valentina ^a   Trincone, Silvana ^a   Vento, Antonella ^a   Sperduti, Isabella ^b   Cristaudo, Antonio ^a   Ensoli, Fabrizio ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; ILOPROST; JO 1 ANTIBODY; KU ANTIGEN; RIBONUCLEOPROTEIN; SCL 70 ANTIBODY; CORTICOTROPIN RELEASING FACTOR; DNA TOPOISOMERASE; TOP1 PROTEIN, HUMAN; UCN2 PROTEIN, HUMAN; UROCORTIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CELL NUCLEUS; CENTROMERE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCLERODERMA; SYSTEMIC SCLEROSIS; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; SCLERODERMA, SYSTEMIC;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORTICOTROPIN-RELEASING HORMONE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; UROCORTINS;

EID: 84879298388     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/390563     Document Type: Article

References (41)

1. Gabrielli A., Avvedimento E. V., Krieg T., Mechanisms of disease: scleroderma. The New England Journal of Medicine 2009 360 19 1989 2003 2-s2.0-65649132626 10.1056/NEJMra0806188
2. Hachulla E., Launay D., Diagnosis and classification of systemic sclerosis. Clinical Reviews in Allergy and Immunology 2011 40 2 78 83 2-s2.0-79951682352 10.1007/s12016-010-8198-y
3. Carwile LeRoy E., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Wollheim F., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. Journal of Rheumatology 1988 15 2 202 205 2-s2.0-0023854176
4. Hamaguchi Y., Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. Journal of Dermatology 2010 37 1 42 53 2-s2.0-75649110071 10.1111/j.1346-8138.2009.00762.x
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis & Rheumatism 1980 23 5 581 590 2-s2.0-0018887574
6. Nadashkevich O., Davis P., Fritzler M. J., A proposal of criteria for the classification of systemic sclerosis. Medical Science Monitor 2004 10 11 CR615 CR621 2-s2.0-9144228790
7. Mosca M., Tani C., Talarico R., Bombardieri S., Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. Autoimmunity Reviews 2011 10 5 256 258 2-s2.0-79952036666 10.1016/j.autrev.2010. 09.013
8. Mosca M., Tani C., Bombardieri S., Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Practice and Research 2007 21 6 1011 1023 2-s2.0-36749050308 10.1016/j.berh.2007.09.004
9. Gabrielli A., Svegliati S., Moroncini G., Avvedimento E. V., Pathogenic autoantibodies in systemic sclerosis. Current Opinion in Immunology 2007 19 6 640 645 2-s2.0-44649085694 10.1016/j.coi.2007.11.004
10. Kuwana M., Kaburaki J., Mimori T., Kawakami Y., Tojo T., Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis 2000. Arthritis & Rheumatism 2000 43 5 1074 1084
11. Lu T. Y. T., Ng K. P., Cambridge G., Leandro M. J., Edwards J. C. W., Ehrenstein M., Isenberg D. A., A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients. Arthritis Care and Research 2009 61 4 482 487 2-s2.0-65249187242 10.1002/art.24341
12. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., Wiethe C., Winkler T. H., Kalden J. R., Manz R. A., Voll R. E., The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nature Medicine 2008 14 7 748 755 2-s2.0-46749088320 10.1038/nm1763
13. Sakaguchi S., Miyara M., Costantino C. M., Hafler D. A., FOXP3 + regulatory T cells in the human immune system. Nature Reviews Immunology 2010 10 7 490 500 2-s2.0-77954141914 10.1038/nri2785
14. Fujio K., Okamura T., Sumitomo S., Yamamoto K., Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity. Annals of the Rheumatic Diseases 2013 72 ii85 ii89 10.1136/annrheumdis-2012- 202341
15. Huber S., Gagliani N., Esplugues E., O'Connor W., Huber F. J., Chaudhry A., Kamanaka M., Kobayashi Y., Booth C. J., Rudensky A. Y., Roncarolo M. G., Battaglia M., Flavell R. A., Th17 cells express IL-10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011 34 4 554 565 2-s2.0-79954620910 10.1016/j.immuni.2011.01.020
16. Chaudhry A., Rudra D., Treuting P., Samstein R. M., Liang Y., Kas A., Rudensky A. Y., CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner. Science 2009 326 5955 986 991 2-s2.0-70049113279 10.1126/science.1172702
17. Cederbom L., Hall H., Ivars F., CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. European Journal of Immunology 2000 30 1538 1543
18. Mehra S., Walker J., Patterson K., Fritzler M. J., Autoantibodies in systemic sclerosis. Autoimmunity Reviews 2013 12 340 354
19. Furst D. E., Clements P. J., Steen V. D., Medsger T. A., Masi A. T., D'Angelo W. A., Lachenbruch P. A., Grau R. G., Seibold J. R., The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. Journal of Rheumatology 1998 25 1 84 88 2-s2.0-0031965195
20. LeRoy E. C., Medsger T. A. Jr., Criteria for the classification of early systemic sclerosis. Journal of Rheumatology 2001 28 7 1573 1576 2-s2.0-0034937852
21. Balbir-Gurman A., Braun-Moscovici Y., Scleroderma overlap syndrome. Israel Medical Association Journal 2011 13 1 14 20 2-s2.0-79551698979
22. Walker U. A., Tyndall A., Czirják L., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Annals of the Rheumatic Diseases 2007 66 754 763
23. Targoff I. N., Johnson A. E., Miller F. W., Antibody to signal recognition particle in polymyositis. Arthritis & Rheumatism 1990 33 9 1361 1370 2-s2.0-0025183975
24. Kao A. H., Lacomis D., Lucas M., Fertig N., Oddis C. V., Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis & Rheumatism 2004 50 1 209 215 2-s2.0-0347719282 10.1002/art.11484
25. Tamby M. C., Chanseaud Y., Guillevin L., Mouthon L., New insights into the pathogenesis of systemic sclerosis. Autoimmunity Reviews 2003 2 3 152 157 2-s2.0-0141819036 10.1016/S1568-9972(03)00004-1
26. Mimura Y., Ihn H., Jinnin M., Asano Y., Yamane K., Tamaki K., Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clinical Rheumatology 2005 24 2 99 102 2-s2.0-17544365221 10.1007/s10067-004- 0975-7
27. Ranque B., Authier F. J., Le-Guern V., Pagnoux C., Berezne A., Allanore Y., Launay D., Hachulla E., Kahan A., Cabane J., Gherardi R., Guillevin L., Mouthon L., A descriptive and prognostic study of systemic sclerosis-associated myopathies. Annals of the Rheumatic Diseases 2009 68 9 1474 1477 2-s2.0-69949166111 10.1136/ard.2008.095919
28. Partovi S., Schulte A. C., Aschwanden M., Impaired skeletal muscle microcirculation in systemic sclerosis. Arthritis Research & Therapy 2012 14 5, article R209
29. Katzap E., Barilla-Labarca M. L., Marder G., Antisynthetase syndrome. Current Rheumatology Reports 2011 13 3 175 181 2-s2.0-79957510404 10.1007/s11926-011-0176-8
30. Kalluri M., Sahn S. A., Oddis C. V., Gharib S. L., Christopher-Stine L., Danoff S. K., Casciola-Rosen L., Hong G., Dellaripa P. F., Highland K. B., Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature. Chest 2009 135 6 1550 1556 2-s2.0-66649121970 10.1378/chest.08-2233
31. Koschik R. W., Fertig N., Lucas M. R., Domsic R. T., Medsger T. A. Jr., Anti-PM-Scl antibody in patients with systemic sclerosis. Clinical and Experimental Rheumatology 2012 30 2, supplement 71 s12 s16
32. Sargent J. L., Whitfield M. L., Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Review of Clinical Immunology 2011 7 4 463 473 2-s2.0-79960908376 10.1586/eci.11.41
33. Wildin R. S., Smyk-Pearson S., Filipovich A. H., Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. Journal of Medical Genetics 2002 39 8 537 545 2-s2.0-0036346861
34. Antiga E., Quaglino P., Bellandi S., Volpi W., Del Bianco E., Comessatti A., Osella-Abate S., De Simone C., Marzano A., Bernengo M. G., Fabbri P., Caproni M., Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. British Journal of Dermatology 2010 162 5 1056 1063 2-s2.0-77951238591 10.1111/j.1365-2133.2010.09633.x
35. Jocea M. R., van Amelsfort M., Walter G. J., Taams L. S., CD4+CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases. Expert Review of Clinical Immunology 2011 7 4 499 514 2-s2.0-79960912511 10.1586/eci.11.28
36. Fenoglio D., Battaglia F., Parodi A., Stringara S., Negrini S., Panico N., Rizzi M., Kalli F., Conteduca G., Ghio M., De Palma R., Indiveri F., Filaci G., Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clinical Immunology 2011 139 3 249 257 2-s2.0-79955974107 10.1016/j.clim.2011.01.013
37. Giovannetti A., Rosato E., Renzi C., Maselli A., Gambardella L., Giammarioli A. M., Palange P., Paoletti P., Pisarri S., Salsano F., Malorni W., Pierdominici M., Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clinical Immunology 2010 137 1 122 133 2-s2.0-77956619921 10.1016/j.clim.2010.06.004
38. Slobodin G., Ahmad M. S., Rosner I., Peri R., Rozenbaum M., Kessel A., Toubi E., Odeh M., Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity. Cellular Immunology 2010 261 2 77 80 2-s2.0-77649178968 10.1016/j.cellimm.2009.12.009
39. Radstake T. R. D. J., van Bon L., Broen J., Wenink M., Santegoets K., Deng Y., Hussaini A., Simms R., Cruikshank W. W., Lafyatis R., Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGF β expression. PLoS ONE 2009 4 6 2-s2.0-67650128154 10.1371/journal.pone.0005981 e5981
40. Katsumoto T. R., Whitfield M. L., Connolly M. K., The pathogenesis of systemic sclerosis. Annual Review of Pathology 2011 6 509 537
41. Hasegawa M., Takehara K., Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Seminars in Arthritis and Rheumatism 2012 42 281 296